Physician profile
Laura Verde
NPI 1982896148
$5,733.27
in general payments reported to CMS, 2019-2025
16 companies · $744 in 2025
The $744 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $663 · 2020: $828 · 2021: $887 · 2022: $675 · 2023: $704 · 2024: $1,232 · 2025: $744.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,681.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,680.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,552.68 | 2019-2023 | Xarelto |
| Medtronic, INC. | $738.77 | 2023-2025 | Azure Xt Dr Mri Surescan, Cobalt Dr Mri Surescan, Ffrangio |
| Edwards Lifesciences Corporation | $702.86 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $564.45 | 2019-2023 | Lifevest |
| Sanofi-Aventis U.S. LLC | $443.12 | 2019-2023 | |
| Abbott Laboratories | $355.94 | 2019-2024 | Gallant, Aveir |
| Boehringer Ingelheim Pharmaceuticals, INC. | $273.42 | 2023-2025 | Jardiance |
| Vanda Pharmaceuticals INC. | $206.08 | 2024-2025 | Fanapt, Hetlioz |
| Medtronic Vascular, INC. | $181.70 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $167.00 | 2019-2024 | |
| Pfizer INC. | $139.43 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $129.47 | 2021-2025 | Camzyos |
| Amgen INC. | $107.14 | 2019-2025 | Repatha |
| Astrazeneca Pharmaceuticals LP | $82.80 | 2019-2023 | Brilinta |
| Novo Nordisk INC | $73.66 | 2021-2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $14.75 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Verde listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.